California Neuroscience Research Medical Group | Sherman Oaks, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Exceptions:
non-metastatic basal- or squamous-cell skin cancer
Stage 0 non-invasive carcinoma of the cervix
Stage 0 non-invasive prostate cancer, or
other cancers with low risk of recurrence or spread
Primary purpose
Allocation
Interventional model
Masking
800 participants in 4 patient groups
Loading...
Central trial contact
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal